Erythropoietin (EPO) Market Forecast Signals New Revenue Opportunities Through 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Erythropoietin (EPO) Market Forecast Highlighting Growth From $21.45 Billion To $35.04 Billion
The market size for erythropoietin (epo) has experienced rapid expansion in recent years. It is projected to increase from $19.25 billion in 2025 to $21.46 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.5%. Historically, this growth has been driven by factors such as a higher prevalence of anemia, a growing occurrence of chronic kidney disease, the well-established clinical efficacy of epo treatment, progress in recombinant biologic production, and the expanding application of epo in managing anemia linked to cancer.
The erythropoietin (epo) market is anticipated to experience substantial expansion in the coming years, reaching an estimated $35.04 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.0%. This forecasted growth is fueled by factors such as the widening approval of biosimilars, an aging global population, a rising number of dialysis patients worldwide, innovations in sustained-release epo formulations, and enhanced access to biologic therapies in developing economies. Key trends shaping the future include the broader application of erythropoietin in managing chronic kidney disease, a greater uptake of biosimilar epo treatments, increasing demand for long-acting versions of the drug, expanded use of epo in supportive oncology care, and tighter regulatory controls concerning epo safety and proper dosing.
Download A Free Sample Report For Comprehensive Market Insights:
Erythropoietin (EPO) Market Growth Momentum: Which Factors Are Influencing Demand?
The growing demand for erythropoietin is expected to be driven by the increasing prevalence of chronic kidney diseases in the coming years. As more individuals develop chronic kidney conditions, the need for erythropoietin administration rises, as it plays a crucial role in producing red blood cells to strengthen the immune system. For example, data from the Centers for Disease Control, a U.S. federal agency, indicates that in 2023, around 14% of American adults—approximately 35.5 million people—are estimated to have chronic kidney disease (CKD). Consequently, this upward trend in chronic kidney disease cases is fueling the requirement for erythropoietin, thereby boosting market revenue.
The anticipated growth of the erythropoietin market is set to be propelled by the rising occurrence of hematologic cancers in the future. Hematologic cancer encompasses malignancies that originate in the blood, affecting the blood, bone marrow, and lymphatic system, with conditions like leukemia, lymphoma, and myeloma being prime examples. In the treatment of cancer-related anemia, erythropoietin (EPO) serves a vital function. By stimulating red blood cell production, it aids in mitigating anemia among cancer patients, especially those receiving chemotherapy. As reported by the American Cancer Society, a U.S.-based nonprofit organization dedicated to cancer elimination, leukemia is predicted to impact 59,610 Americans in 2023 and result in 23,710 fatalities. Additionally, new cases of non-Hodgkin lymphoma are expected to affect 80,550 people across the United States, causing 20,180 deaths. Hence, the growing incidence of hematologic cancers is driving the expansion of the erythropoietin market.
Erythropoietin (EPO) Market Segment Landscape And Growth Potential
The erythropoietin (epo) market covered in this report is segmented –
1) By Product: Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Other Products
2) By Drug Class: Biologist, Biosimilar
3) By Application: Cancer, Hematology, Renal Diseases, Neurology, Other Applications
Subsegments:
1) By Epoetin-Alfa: Epoetin-Alfa, Epoetin-Alfa Biosimilars
2) By Epoetin-Beta: Epoetin-Beta, Epoetin-Beta Biosimilars
3) By Darbepoetin-Alfa: Darbepoetin-Alfa, Darbepoetin-Alfa Biosimilars
4) By Other Products: Peginesatide, Novel EPO Products
Erythropoietin (EPO) Market Trends Reshaping Industry Growth
Leading players in the erythropoietin market are prioritizing the development of oral medications, which serve as a simpler substitute for standard injectable treatments. This strategy is designed to enhance patient ease, adherence, and therapeutic adaptability, especially for those coping with long-term illnesses such as anemia linked to chronic kidney disease (CKD). For example, in February 2023, GlaxoSmithKline (GSK), a prominent UK-based pharmaceutical and biotech firm, introduced Jesduvroq (daprodustat) tablets. This oral drug works by elevating erythropoietin production to control anemia in CKD patients, ensuring hemoglobin levels remain within a specified range. The primary objective of Jesduvroq is to deliver a more practical option than injectable therapies, thereby boosting patient comfort, compliance, and treatment versatility for those undergoing dialysis.
Erythropoietin (EPO) Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the erythropoietin (epo) market are Amgen Inc., Roche Holding AG, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Ltd., 3SBio Inc., Celltrion Inc., Intas Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Reliance Life Sciences Pvt. Ltd., Biocon Limited, Chugai Pharmaceutical Co., Kyowa Kirin Co. Ltd., Apotex Inc., CJ Healthcare Corp., STADA Arzneimittel AG, Hospira Inc., Sandoz International GmbH, Torrent Pharmaceuticals Ltd., LG Life Sciences Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals.
Access The Complete Erythropoietin (EPO) Market Report:
Erythropoietin (EPO) Market Largest Region By Revenue And Market Share
North America was the largest region in the erythropoietin (EPO) market in 2025. The Middle East is expected to be the fastest growing region in the global erythropoietin (EPO) market analysis in the forecast period. The regions covered in the erythropoietin (epo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
